National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)’s Post

https://lnkd.in/e8wWvQDR Thought provoking retrospective article recommending α-blocker prophylaxis in post operative CHD patients. Great Q&A as well discussing the study results and conclusion as well as which patients postoperatively had an effective response to INO.

Exciting results from the DELIVER clinical trial extension study on eptinezumab for migraine treatment! It was found to effectively prevent migraine attacks in patients with prior treatment failures, supporting its long-term use. This trial included 865 adults living with migraine, previously experiencing 2–4 preventive treatment failures. Notable Findings: 🌟 Mean change from baseline in Monthly Migraine Days (MMDs) during the final dosing interval (weeks 61–72): - Placebo/Eptinezumab 100 mg: -6.4 days - Placebo/Eptinezumab 300 mg: -7.3 days - Eptinezumab 100 mg: -7.1 days - Eptinezumab 300 mg: -7.0 days 🌟 63–70% of patients achieved ≥ 50% reduction in MMDs and 36–45% demonstrated ≥ 75% reduction during weeks 61-72. 🌟 Improvements in headache severity, acute medication use, quality of life, and work productivity. Read the full study at https://lnkd.in/envBXAZh #MigraineTreatment #MigraineResearch #Eptinezumab

The American Diabetes Association returns for its 84th Annual Scientific Session on June 21st, bringing together researchers, healthcare professionals, and industry experts to delve into the latest advancements in diabetes research, treatment, and care.    With session themes focusing on therapeutics, management of acute or chronic complications, and behavioural medicine, it’s worth highlighting that the effectiveness of any treatment depends on its efficacy, safety, and patient adherence. Patient-centric integrated care approaches that enable real-time patient monitoring play a pivotal role in ensuring medication adherence and mitigating the risk and severity of complications associated with obesity, such as diabetes and hypertension.   Get in touch to arrange a meeting with Hakim Yadi Ph.D. OBE! Learn more about how Closed Loop Medicine is facilitating personalized disease management through our expanding portfolio of drug-plus-software combination products, to improve the effectiveness of medicines, such as GLP-1s, while reducing the impact of adverse effects:  https://shorturl.at/fMcea   #ADA2024 #TechBio #PrecisionCare

Meropenem infusion options in sepsis - Full Text... "The aim of this study was to compare the clinical effectiveness of prolonged infusion and intermittent infusion of meropenem in patients with sepsis" Lokhandwala et al (2023).

Meropenem infusion options in sepsis - Full Text... "The aim of this study was to compare the clinical effectiveness of prolonged infusion and intermittent infusion of meropenem in patients with sepsis" Lokhandwala et al (2023).

In cases of amlodipine overdose, Cytosorb emerges as a potential game-changer. Amlodipine, a commonly prescribed calcium channel blocker, can trigger severe cardiovascular complications when overdosed, leading to organ damage and failure, particularly impacting the heart. Cytosorb's remarkable ability to adsorb not only inflammatory mediators and cytokines but also amlodipine itself presents a significant advantage. By effectively modulating inflammatory responses and stabilizing hemodynamics, Cytosorb aids in mitigating secondary inflammatory reactions associated with organ damage and shock. Its role as a supportive therapy is paramount, working in tandem with standard protocols for overdose management, including supportive care and specific antidotes. This breakthrough underscores Cytosorb's versatility in critical care settings and highlights its potential to revolutionize treatment paradigms in severe overdose scenarios. Consulting healthcare professionals for tailored solutions remains pivotal in optimizing patient outcomes. Explore how Cytosorb can transform critical care management and elevate patient care standards. #Cytosorb #CriticalCare #AmlodipineOverdose #InnovativeTherapies #HealthcareRevolution

🌟 Exciting News in Healthcare 🌟 The U.S. FDA's recent approval of Wegovy (semaglutide) injection for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight marks a major milestone in addressing the intersection of obesity and cardiovascular health. This groundbreaking development not only offers a novel approach to weight management but also contributes to preventing life-threatening cardiovascular events in a high-risk patient population. Wegovy's efficacy and safety, as demonstrated in a rigorous multi-national, multi-center trial, showcased a significant reduction in major adverse cardiovascular events compared to a placebo, reaffirming its potential as a game-changer in public health. This approval also presents an opportunity for informed discussions among healthcare professionals and patients alike, regarding the management of cardiovascular risk in individuals with obesity or overweight. Furthermore, major advances such as this underscore the importance of ongoing research and innovation in addressing the complex nexus of cardiovascular disease and metabolic health. As we celebrate this pivotal moment, it's crucial to recognize the collaborative efforts and dedication of the healthcare community in striving towards impactful solutions. Congratulations to Novo Nordisk A/S for this significant achievement, and here's to a future of improved cardiovascular outcomes and enhanced patient care. #HealthcareInnovation #CardiovascularHealth #ObesityManagement #PublicHealth #MedicalAdvancements

Register now for our McMaster Nephrology Update on May 31. By attending, you will be able to: - Learn how to advance health equity within kidney disease. - Apply an approach to the identification, diagnosis, and management of chronic kidney disease. - Identify resources available to primary care providers for assisting in the identification and management of chronic kidney disease. - Understand when and how to use new and emerging therapies in the management of chronic kidney disease. - Determine which patients require nephrology referral and which can be managed by their primary care provider and be able to counsel their patients in this regard. - Develop a basic understanding of renal transplantation and an approach to post-transplantation primary care. - Develop an approach to dietary counselling for patients with chronic kidney disease. - Apply an approach to the diagnosis and management of hyponatremia and hyperkalemia in the outpatient setting. Sign up at: https://lnkd.in/gyMfysd2 #MacCPD #LifelongLearning #SkillsDevelopment #MedicalEducation #ProfessionalDevelopment

The SGLT2 Inhibitors are here to stay! Already showing many benefits for improved glycemic control among Type 2 diabetics, and mortality benefits for patients with heart failure, this really well done review confirms the value of these agents on quality of life for patients with heart failure, regardless of their diabetic status. It is great to have one more class of medicine that can aid in better management of two of the most prevalent chronic issues (diabetes and heart failure) but also improve patient quality of life. AMDA - The Society for Post-Acute and Long-Term Care Medicine BrightSpring Health Services Abode Care Partners #empagliflozin #dapagliflozin #canagliflozin #sotagliflozin #qualityoflife #evidencebasedcare

There's an interesting article in JMCP about the rise of the prevalence of NASH (nonalcoholic steatohepatitis)/MASH (metabolic dysfunction–associated steatohepatitis) and how it's closely linkedto obesity and type 2 diabetes. Early diagnosis is crucial for preventing progression to liver fibrosis, cirrhosis, or hepatocellular carcinoma (HCC). 🩺 This article is well-written (so kudos to Dr. Bridget Flavin!). If anything, you should check out Table 1 that does a side-by-side comparison of the guideline recommendations. Also, I personally wish that the powers that be would definitively settle on the NASH/MASH (and comparable NAFLD). The AASLD has settled on the more inclusive MASH/MASLD nomenclature, but many groups and publications are still using the "nonalcoholic" verbiage. Resmetirom, the first FDA-approved treatment specifically for MASH, is a key development, but its integration into patient care comes with challenges. Managed care organizations (MCOs) must balance its high cost, patient access, and clinical benefit while preparing for emerging treatments. 🏥 For MCOs, understanding patient perspectives is critical, especially in addressing health disparities and ensuring equitable access to care. Multidisciplinary approaches and personalized interventions can enhance both patient outcomes and the effectiveness of new therapies. 🚑 What's your take on this? Plus, do you have any thoughts about the switch to the metabolic verbiage versus nonalcoholic? You can check out the entire article at https://buff.ly/4dRE5Vl #MASH #ManagedCare #PrecisionMedicine #MedicalWriting